+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD329 mouse mAb (green) and negative control (red).    

  
  

CD329. also known as Siglec-3 or CD33-like lectin, is a member of the sialic acid-binding immunoglobulin-type lectin (Siglec) family. It is a transmembrane glycoprotein primarily expressed on myeloid cells, including monocytes, macrophages, dendritic cells, and microglia. Structurally, CD329 contains an extracellular V-set immunoglobulin domain that mediates sialic acid recognition and cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) involved in signaling. Functionally, it acts as an inhibitory receptor, modulating immune responses by dampening cellular activation through ITIM-dependent recruitment of phosphatases like SHP-1/SHP-2. This regulatory role makes CD329 critical in maintaining immune homeostasis and preventing excessive inflammation.

CD329 has garnered attention in disease research, particularly in cancer and neurodegenerative disorders. In hematologic malignancies, such as acute myeloid leukemia (AML), CD329 is overexpressed on malignant cells and serves as a diagnostic marker and therapeutic target. Antibodies targeting CD329 are explored for antibody-drug conjugates (ADCs) or CAR-T cell therapies to eliminate cancerous cells. In Alzheimer’s disease, CD329’s involvement in neuroinflammation and microglial activation has prompted studies on its role in disease progression. Commercially available CD329 antibodies are widely used in flow cytometry, immunohistochemistry, and functional studies to characterize cell populations or signaling pathways. Recent research also investigates its interactions with pathogens, including HIV-1. which may exploit CD329 for immune evasion. Despite progress, the full scope of CD329’s biological roles and therapeutic potential remains under active investigation.